The 7 Legal Mistakes US Biotech Companies Make When Expanding into Europe

Key Takeaways

• Europe is not a single market. 

• Data governance and AI issues often arise earlier than expected. 

• IP ownership issues can affect financings, partnerships and exits. 

• European diligence requirements are frequently underestimated.

Introduction

For many US biotech companies, Europe becomes relevant immediately after a successful financing round, a pivotal clinical milestone, or the beginning of commercialization planning.

Yet many companies discover that Europe is considerably more complex than expected. Assumptions that work well in the United States often do not translate smoothly across Europe.

Over the years, we have seen the same issues or ‘mistakes’ appear repeatedly. While they are rarely catastrophic, they often create delays, complicate financing discussions, and they occasionally derail strategic opportunities altogether.

Here are seven of the most common mistakes:

1. Treating Europe as a Single Market

One of the most persistent misconceptions is the belief that Europe functions like the United States. It does not.

While the European Union provides a common legal framework in many areas, significant differences remain between individual countries. 

This is particularly relevant for biotech companies conducting clinical development activities. While the EU Clinical Trials Regulation has harmonized important aspects of the approval process, significant differences remain in practice. Site selection, patient recruitment, ethics committee procedures, investigator networks and operational timelines can vary considerably between jurisdictions.

Clinical trial practices vary. Healthcare reimbursement systems differ dramatically. Employment law, commercial customs, and tax considerations are local. 

Even where EU regulations apply, implementation and enforcement may differ from country to country.

US companies that approach Europe with a "one-size-fits-all" strategy frequently discover that assumptions made in one jurisdiction do not translate smoothly into another.

In our practice, we often see that the most successful expansion strategies start by identifying priority jurisdictions, rather than by attempting to address Europe as a whole.

2. Waiting Too Long to Address Data and AI Issues

Many biotech companies today rely heavily on data: Clinical data, patient data, research data, and increasingly artificial intelligence.

US companies often discover that European requirements regarding data governance are more extensive than anticipated.

The GDPR is only one part of the equation.

Questions surrounding lawful data access, cross-border data transfers, AI governance, and contractual data rights can become material issues long before commercial launch.

For AI-enabled healthcare businesses, the EU AI Act adds another layer of complexity.

A typical mistake many US companies make is to wait until a product is already deployed before assessing whether the regulatory framework has implications for the business model. 

3. Underestimating Intellectual Property Ownership Issues

Many biotech companies are built on licensed technologies, university collaborations and joint development arrangements. 

European transactions often involve different expectations regarding ownership of improvements, background IP, publication rights, access rights, and tech transfer obligations.

Issues that appear straightforward during early-stage negotiations can become significant during later financings. Investors, strategic partners and acquirers increasingly scrutinize IP chains of title because ownership uncertainties can directly affect valuation and transaction execution. A small inconsistency in a collaboration agreement signed years earlier can create substantial diligence challenges later.

4. Using US Contract Templates for European Transactions

US documentation often provides a useful starting point. But it rarely provides a complete solution. This is particularly true for licensing agreements, sponsored research agreements and translational medicine collaborations, CDMO and supply arrangements, data-sharing arrangements, and commercial partnerships. 

Concepts that are familiar in US agreements may have different legal effects under European law. Other issues that receive little attention in US contracts may require detailed treatment in Europe. Oftentimes, the result is an agreement that does not allocate risk in the way the parties intended.

For US companies entering Europe, transaction documents should be reviewed through both a legal and commercial lens.

5. Failing to Prepare for European Due Diligence

Many companies focus on legal compliance only when a financing, acquisition or strategic partnership becomes imminent.

That is often too late. Issues that remain invisible during day-to-day operations often surface immediately during a financing round or acquisition process.

European diligence reviews increasingly examine data governance, AI governance, IP ownership, cybersecurity, contractual frameworks and regulatory compliance.  

Oftentimes, unprepared companies will find that they lack the required documentation showing that risks have been identified and managed appropriately. 

Well-prepared companies generally experience smoother transactions, fewer diligence questions and stronger negotiating positions. 

6. Ignoring Local Commercial Reality

Expansions are frequently driven by scientific and regulatory considerations. However, commercial factors deserve equal attention. 

You should address the following questions early: Which jurisdiction should host the European headquarters? Where should commercial teams be located? Which countries should be entered first? How should distributor relationships be structured? How should local partnerships be managed?

Legal structures should support commercial strategy. Too often, companies select structures based solely on legal or tax considerations without considering operational realities.

7. Treating European Legal Advice as a Compliance Exercise

Perhaps the most common mistake is viewing legal support purely as a compliance function.

The companies that succeed in Europe typically use legal advisers differently. They involve advisers early. They use legal input to identify risks before they become problems. They integrate legal considerations into business planning, partnership discussions and investment decisions.

In other words, they view legal strategy as part of commercial strategy. That approach generally produces better outcomes and lower costs over time.

Final Thoughts

Europe remains one of the most attractive growth markets for biotech companies. The opportunities are significant, but so are the complexities.

The good news is that most expansion challenges are manageable when addressed early and strategically.

The companies that achieve the smoothest European expansion are rarely those with the largest legal budgets. They are usually the companies that identify the relevant issues before they become obstacles to growth.

Investor Perspective

For investors, European legal readiness is increasingly becoming a value creation issue rather than a compliance issue.

Before a portfolio company expands into Europe, investors may wish to ask: 

• Does the company process European personal data?

• Are there AI Act implications?

• Is the IP ownership chain clean?

• Would the company withstand a European diligence review?

• Has the optimal market-entry strategy been identified?

Data governance, AI regulation, IP ownership and transaction preparedness can materially influence financing outcomes, strategic partnerships and exit opportunities.

Assessing these topics early often creates significantly more value than addressing them during a transaction process.